GlassScriptPhysician profile
Jennifer A Mize
NPI 1457836405
$4,306.85
in general payments reported to CMS, 2019-2025
19 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,139 · 2022: $1,442 · 2023: $1,228 · 2024: $368 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,333.57 | 2021-2025 | |
| Janssen Biotech, INC. | $324.43 | 2021-2023 | Stelara |
| Nestle Healthcare Nutrition INC. | $230.86 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.11 | 2021-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $166.64 | 2021-2023 | Entyvio |
| Gilead Sciences, INC. | $160.65 | 2021-2023 | |
| Genzyme Corporation | $146.95 | 2022-2023 | |
| Celgene Corporation | $120.17 | 2022-2023 | Zeposia |
| Sirtex Medical INC | $118.38 | 2024 | Sir-Spheres Microspheres |
| Madrigal Pharmaceuticals | $116.95 | 2025 | Rezdiffra |
| Qol Medical, LLC | $105.57 | 2021-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $87.63 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $84.13 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $45.11 | 2023 | Dificid, Zerbaxa |
| Braintree Laboratories, INC. | $33.36 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $16.87 | 2021 | |
| Pfizer INC. | $16.47 | 2023 | |
| Organon LLC | $14.27 | 2023 | Renflexis |
| Ferring Pharmaceuticals INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.